ReForm and MilliporeSigma agree excipient development and commercialization deal

11 Feb 2020

Merck KGaA’s US life science arm, MilliporeSigma, has signed a global licence agreement with biologics technology firm ReForm Biologics to commercialize the latter’s proprietary excipients used in biotherapeutic formulations.

Under the terms of the deal, both companies will conduct research, development and qualification of ReForm’s excipients for pharmaceutical use.

ReForm and MilliporeSigma agree excipient development and commercialization deal

MilliporeSigma will fund the R&D and be responsible for global commercialization, GMP manufacturing and sale of ReForm excipients.

ReForm will receive revenues from Millipore Sigma for sublicensing its patented technology platform.

“This agreement will make ReForm Biologics’ excipients available through their GMP manufacturing and distribution network, accelerate our research and development activities, and greatly expand our presence in biological drug development,” said John M. Sorvillo, CEO at ReForm Biologics.

“As more biologics are being developed to treat a broad range of diseases ranging from cancer to orphan indications, we believe there will be a growing demand for new excipients that can enhance the patient experience, improve patient outcomes, and potentially extend the patent life of a therapeutic.“